Jump to main content
Jump to site search

Issue 5, 2015
Previous Article Next Article

Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties

Author affiliations

Abstract

A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parameters, confirmation of receptor occupancy through ex vivo binding and efficacy in a rat sleep model. A key feature of the series is a short dissociation half-life, measured by surface plasmon resonance (SPR) using stabilized receptors, and confirmed by radioligand-binding experiments. Based on a consideration of the requirements for a potential treatment for insomnia, compound 27 was identified as having the best balance of properties from the chemical series.

Graphical abstract: Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties

Back to tab navigation

Supplementary files

Publication details

The article was received on 20 Jan 2015, accepted on 26 Mar 2015 and first published on 30 Mar 2015


Article type: Concise Article
DOI: 10.1039/C5MD00027K
Author version
available:
Download author version (PDF)
Med. Chem. Commun., 2015,6, 947-955

  •   Request permissions

    Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties

    J. A. Christopher, S. J. Aves, J. Brown, J. C. Errey, S. S. Klair, C. J. Langmead, O. J. Mace, R. Mould, J. C. Patel, B. G. Tehan, A. Zhukov, F. H. Marshall and M. Congreve, Med. Chem. Commun., 2015, 6, 947
    DOI: 10.1039/C5MD00027K

Search articles by author

Spotlight

Advertisements